-
1
-
-
84975856269
-
Economic costs of diabetes in the U.S. in 2012
-
American Diabetes Association
-
Economic costs of diabetes in the U.S. in 2012. American Diabetes Association, Diabetes Care 2013 36 4 1033 1046
-
(2013)
Diabetes Care
, vol.36
, Issue.4
, pp. 1033-1046
-
-
-
2
-
-
84861922360
-
Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs
-
Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Hex N, Bartlett C, Wright D, Taylor M, Varley D, Diabet Med 2012 29 7 855 862
-
(2012)
Diabet Med
, vol.29
, Issue.7
, pp. 855-862
-
-
Hex, N.1
Bartlett, C.2
Wright, D.3
Taylor, M.4
Varley, D.5
-
3
-
-
80052245888
-
Health and economic burden of the projected obesity trends in the USA and the UK
-
Health and economic burden of the projected obesity trends in the USA and the UK. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M, Lancet 2011 378 9793 815 825
-
(2011)
Lancet
, vol.378
, Issue.9793
, pp. 815-825
-
-
Wang, Y.C.1
McPherson, K.2
Marsh, T.3
Gortmaker, S.L.4
Brown, M.5
-
4
-
-
2342466734
-
Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030
-
DOI 10.2337/diacare.27.5.1047
-
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H, Diabetes Care 2004 27 5 1047 1053 (Pubitemid 38579764)
-
(2004)
Diabetes Care
, vol.27
, Issue.5
, pp. 1047-1053
-
-
Wild, S.1
Roglic, G.2
Green, A.3
Sicree, R.4
King, H.5
-
5
-
-
33845338724
-
Projections of global mortality and burden of disease from 2002 to 2030
-
Projections of global mortality and burden of disease from 2002 to 2030. Mathers CD, Loncar D, PLoS Med 2006 3 11 442
-
(2006)
PLoS Med
, vol.3
, Issue.11
, pp. 5442
-
-
Mathers, C.D.1
Loncar, D.2
-
7
-
-
84855185039
-
Standards of medical care in diabetes-2012
-
American Diabetes Association
-
Standards of medical care in diabetes-2012. American Diabetes Association, Diabetes Care 2012 35 Suppl 1 11 63
-
(2012)
Diabetes Care
, vol.35
, Issue.SUPPL. 1
, pp. 1911-1963
-
-
-
8
-
-
60449089649
-
European association for study of D: Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American diabetes association and the European association for the study of diabetes
-
European association for study of D: medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American diabetes association and the European association for the study of diabetes. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, Diabetes Care 2009 32 1 193 203
-
(2009)
Diabetes Care
, vol.32
, Issue.1
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
Ferrannini, E.4
Holman, R.R.5
Sherwin, R.6
Zinman, B.7
-
9
-
-
84871995815
-
Standards of medical care in diabetes-2013
-
American Diabetes Association
-
Standards of medical care in diabetes-2013. American Diabetes Association, Diabetes Care 2013 36 Suppl 1 11 66
-
(2013)
Diabetes Care
, vol.36
, Issue.SUPPL. 1
, pp. 1911-1966
-
-
-
10
-
-
0027370108
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
-
Diabetes Control and Complications Trial Research Group
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial Research Group, N Engl J Med 1993 329 14 977 986
-
(1993)
N Engl J Med
, vol.329
, Issue.14
, pp. 977-986
-
-
-
11
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
-
Prospective Diabetes Study (ukpds) Group U.K.
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group, Lancet 1998 352 9131 854 865
-
(1998)
Lancet
, vol.352
, Issue.9131
, pp. 854-865
-
-
-
12
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK prospective diabetes study (UKPDS) group
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group, Lancet 1998 352 9131 837 853
-
(1998)
Lancet
, vol.352
, Issue.9131
, pp. 837-853
-
-
-
13
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD)
-
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), Diabetes Care 2012 35 6 1364 1379
-
(2012)
Diabetes Care
, vol.35
, Issue.6
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
Diamant, M.4
Ferrannini, E.5
Nauck, M.6
Peters, A.L.7
Tsapas, A.8
Wender, R.9
Matthews, D.R.10
-
14
-
-
84877934780
-
Glycemic control and diabetes-related health care costs in type 2 diabetes; Retrospective analysis based on clinical and administrative databases
-
Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases. Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E, Clinicoecon Outcomes Res 2013 5 193 201
-
(2013)
Clinicoecon Outcomes Res
, vol.5
, pp. 193-201
-
-
Degli Esposti, L.1
Saragoni, S.2
Buda, S.3
Sturani, A.4
Degli Esposti, E.5
-
15
-
-
84876799953
-
-
National Collaborating Centre for Chronic Conditions Centre for Clinical Practice at the National Institute for Health and Care Excellence
-
National Collaborating Centre for Chronic Conditions, Centre for Clinical Practice at the National Institute for Health and Care Excellence, NICE Clinical Guideline 87, Type 2 diabetes: the management of type 2 diabetes 2009 http://www.nice.org.uk
-
(2009)
NICE Clinical Guideline 87, Type 2 Diabetes: The Management of Type 2 Diabetes
-
-
-
16
-
-
35348922328
-
Contraindications to metformin therapy among patients with type 2 diabetes mellitus
-
DOI 10.1007/s11096-007-9095-1
-
Contraindications to metformin therapy among patients with type 2 diabetes mellitus. Sweileh WM, Pharm World Sci 2007 29 6 587 592 (Pubitemid 47594163)
-
(2007)
Pharmacy World and Science
, vol.29
, Issue.6
, pp. 587-592
-
-
Sweileh, W.M.1
-
17
-
-
77953845365
-
Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes
-
Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Barnett AH, Cradock S, Fisher M, Hall G, Hughes E, Middleton A, Int J Clin Pract 2010 64 8 1121 1129
-
(2010)
Int J Clin Pract
, vol.64
, Issue.8
, pp. 1121-1129
-
-
Barnett, A.H.1
Cradock, S.2
Fisher, M.3
Hall, G.4
Hughes, E.5
Middleton, A.6
-
18
-
-
64249145623
-
Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents
-
Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Hauber AB, Mohamed AF, Johnson FR, Falvey H, Diabet Med 2009 26 4 416 424
-
(2009)
Diabet Med
, vol.26
, Issue.4
, pp. 416-424
-
-
Hauber, A.B.1
Mohamed, A.F.2
Johnson, F.R.3
Falvey, H.4
-
19
-
-
77954189321
-
The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus
-
The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Pi-Sunyer FX, Postgrad Med 2009 121 5 94 107
-
(2009)
Postgrad Med
, vol.121
, Issue.5
, pp. 94-107
-
-
Pi-Sunyer, F.X.1
-
20
-
-
43449100355
-
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the real-life effectiveness and care patterns of diabetes management (RECAP-DM) study
-
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D, Diabetes Obes Metab 2008 10 Suppl 1 25 32
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.SUPPL. 1
, pp. 25-32
-
-
Alvarez Guisasola, F.1
Tofe Povedano, S.2
Krishnarajah, G.3
Lyu, R.4
Mavros, P.5
Yin, D.6
-
21
-
-
79960969194
-
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes
-
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L, Look AHEAD Research Group, Diabetes Care 2011 34 7 1481 1486
-
(2011)
Diabetes Care
, vol.34
, Issue.7
, pp. 1481-1486
-
-
Wing, R.R.1
Lang, W.2
Wadden, T.A.3
Safford, M.4
Knowler, W.C.5
Bertoni, A.G.6
Hill, J.O.7
Brancati, F.L.8
Peters, A.9
Wagenknecht, L.10
-
22
-
-
67349180574
-
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects
-
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M, Clin Pharmacol Ther 2009 85 5 520 526
-
(2009)
Clin Pharmacol Ther
, vol.85
, Issue.5
, pp. 520-526
-
-
Komoroski, B.1
Vachharajani, N.2
Boulton, D.3
Kornhauser, D.4
Geraldes, M.5
Li, L.6
Pfister, M.7
-
23
-
-
79952221451
-
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
-
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. List JF, Whaley JM, Kidney Int Suppl 2011 120 20 27
-
(2011)
Kidney Int Suppl
, vol.120
, pp. 1920-1927
-
-
List, J.F.1
Whaley, J.M.2
-
24
-
-
84858020943
-
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
-
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S, J Clin Endocrinol Metab 2012 97 3 1020 1031
-
(2012)
J Clin Endocrinol Metab
, vol.97
, Issue.3
, pp. 1020-1031
-
-
Bolinder, J.1
Ljunggren, O.2
Kullberg, J.3
Johansson, L.4
Wilding, J.5
Langkilde, A.M.6
Sugg, J.7
Parikh, S.8
-
25
-
-
84860218907
-
Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
-
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF, Int J Clin Pract 2012 66 5 446 456
-
(2012)
Int J Clin Pract
, vol.66
, Issue.5
, pp. 446-456
-
-
Henry, R.R.1
Murray, A.V.2
Marmolejo, M.H.3
Hennicken, D.4
Ptaszynska, A.5
List, J.F.6
-
26
-
-
84873960885
-
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial
-
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF, BMC Med 2013 11 43
-
(2013)
BMC Med
, vol.11
, pp. 43
-
-
Bailey, C.J.1
Gross, J.L.2
Hennicken, D.3
Iqbal, N.4
Mansfield, T.A.5
List, J.F.6
-
27
-
-
77953857048
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF, Lancet 2010 375 9733 2223 2233
-
(2010)
Lancet
, vol.375
, Issue.9733
, pp. 2223-2233
-
-
Bailey, C.J.1
Gross, J.L.2
Pieters, A.3
Bastien, A.4
List, J.F.5
-
28
-
-
77956921439
-
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
-
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF, Diabetes Care 2010 33 10 2217 2224
-
(2010)
Diabetes Care
, vol.33
, Issue.10
, pp. 2217-2224
-
-
Ferrannini, E.1
Ramos, S.J.2
Salsali, A.3
Tang, W.4
List, J.F.5
-
29
-
-
80155124676
-
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
-
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ, Diabetes Care 2011 34 9 2015 2022
-
(2011)
Diabetes Care
, vol.34
, Issue.9
, pp. 2015-2022
-
-
Nauck, M.A.1
Del Prato, S.2
Meier, J.J.3
Duran-Garcia, S.4
Rohwedder, K.5
Elze, M.6
Parikh, S.J.7
-
30
-
-
84862875221
-
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy
-
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Rosenstock J, Vico M, Wei L, Salsali A, List JF, Diabetes Care 2012 35 7 1473 1478
-
(2012)
Diabetes Care
, vol.35
, Issue.7
, pp. 1473-1478
-
-
Rosenstock, J.1
Vico, M.2
Wei, L.3
Salsali, A.4
List, J.F.5
-
31
-
-
80052524011
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S, Diabetes Obes Metab 2011 13 10 928 938
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.10
, pp. 928-938
-
-
Strojek, K.1
Yoon, K.H.2
Hruba, V.3
Elze, M.4
Langkilde, A.M.5
Parikh, S.6
-
32
-
-
84858323889
-
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial
-
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S, Dapagliflozin 006 Study Group, Ann Intern Med 2012 156 6 405 415
-
(2012)
Ann Intern Med
, vol.156
, Issue.6
, pp. 405-415
-
-
Wilding, J.P.1
Woo, V.2
Soler, N.G.3
Pahor, A.4
Sugg, J.5
Rohwedder, K.6
Parikh, S.7
-
33
-
-
79959925787
-
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1
-
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Jansen J, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC, Value Health 2011 14 417 428
-
(2011)
Value Health
, vol.14
, pp. 417-428
-
-
Jansen, J.1
Fleurence, R.2
Devine, B.3
Itzler, R.4
Barrett, A.5
Hawkins, N.6
Lee, K.7
Boersma, C.8
Annemans, L.9
Cappelleri, J.C.10
-
35
-
-
80755180389
-
-
National Institute for Health Care Excellence
-
National Institute for Health and Care Excellence, Guide to the methods of technology appraisal 2013 http://www.nice.org.uk
-
(2013)
Guide to the Methods of Technology Appraisal
-
-
-
36
-
-
26944454062
-
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence
-
Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Caldwell DM, Ades AE, Higgins JP, BMJ 2005 331 7521 897 900 (Pubitemid 41502718)
-
(2005)
British Medical Journal
, vol.331
, Issue.7521
, pp. 897-900
-
-
Caldwell, D.M.1
Ades, A.E.2
Higgins, J.P.T.3
-
37
-
-
5044221416
-
Combination of direct and indirect evidence in mixed treatment comparisons
-
DOI 10.1002/sim.1875
-
Combination of direct and indirect evidence in mixed treatment comparisons. Lu G, Ades AE, Stat Med 2004 23 20 3105 3124 (Pubitemid 39334902)
-
(2004)
Statistics in Medicine
, vol.23
, Issue.20
, pp. 3105-3124
-
-
Lu, G.1
Ades, A.E.2
-
38
-
-
51149095603
-
Use of indirect and mixed treatment comparisons for technology assessment
-
Use of indirect and mixed treatment comparisons for technology assessment. Sutton A, Ades AE, Cooper N, Abrams K, Pharmacoeconomics 2008 26 9 753 767
-
(2008)
Pharmacoeconomics
, vol.26
, Issue.9
, pp. 753-767
-
-
Sutton, A.1
Ades, A.E.2
Cooper, N.3
Abrams, K.4
-
39
-
-
46749154951
-
Evaluation of networks of randomized trials
-
Evaluation of networks of randomized trials. Salanti G, Higgins JP, Ades AE, Loannidis JP, Stat Methods Med Res 2008 17 3 279 301
-
(2008)
Stat Methods Med Res
, vol.17
, Issue.3
, pp. 279-301
-
-
Salanti, G.1
Higgins, J.P.2
Ades, A.E.3
Loannidis, J.P.4
-
40
-
-
67649303082
-
A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered
-
A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. Salanti G, Marinho V, Higgins JP, J Clin Epidemiol 2009 62 8 857 864
-
(2009)
J Clin Epidemiol
, vol.62
, Issue.8
, pp. 857-864
-
-
Salanti, G.1
Marinho, V.2
Higgins, J.P.3
-
42
-
-
18944371703
-
Type 2 diabetes market
-
DOI 10.1038/nrd1723
-
Type 2 diabetes market. Gershell L, Nat Rev Drug Discov 2005 4 5 367 368 (Pubitemid 40704113)
-
(2005)
Nature Reviews Drug Discovery
, vol.4
, Issue.5
, pp. 367-368
-
-
Gershell, L.1
-
43
-
-
41049110803
-
New drugs for the treatment of diabetes part II: Incretin-based therapy and beyond
-
New drugs for the treatment of diabetes part II: incretin-based therapy and beyond. Inzucchi SE, McGuire DK, Circulation 2008 117 4 574 584
-
(2008)
Circulation
, vol.117
, Issue.4
, pp. 574-584
-
-
Inzucchi, S.E.1
McGuire, D.K.2
-
46
-
-
0030793120
-
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials
-
DOI 10.1016/S0895-4356(97)00049-8, PII S0895435697000498
-
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Bucher HC, Guyatt GH, Griffith LE, Walter SD, J Clin Epidemiol 1997 50 6 683 691 (Pubitemid 27341818)
-
(1997)
Journal of Clinical Epidemiology
, vol.50
, Issue.6
, pp. 683-691
-
-
Bucher, H.C.1
Guyatt, G.H.2
Griffith, L.E.3
Walter, S.D.4
-
47
-
-
69749100189
-
Indirect comparison: Relative risk fallacies and odds solution
-
Indirect comparison: relative risk fallacies and odds solution. Eckermann S, Coory M, Willan AR, J Clin Epidemiol 2009 62 10 1031 1036
-
(2009)
J Clin Epidemiol
, vol.62
, Issue.10
, pp. 1031-1036
-
-
Eckermann, S.1
Coory, M.2
Willan, A.R.3
-
49
-
-
43749097000
-
Metan: Fixed- and random-effects meta-analysis
-
metan: fixed- and random-effects meta-analysis. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J, Stata J 2008 8 1 3 28
-
(2008)
Stata J
, vol.8
, Issue.1
, pp. 3-28
-
-
Harris, R.1
Bradburn, M.2
Deeks, J.3
Harbord, R.4
Altman, D.5
Sterne, J.6
-
50
-
-
84904262910
-
Software updates (sbe24-3)
-
Software updates (sbe24-3). Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J, Stata J 2008 9 2 327
-
(2008)
Stata J
, vol.9
, Issue.2
, pp. 327
-
-
Harris, R.1
Bradburn, M.2
Deeks, J.3
Harbord, R.4
Altman, D.5
Sterne, J.6
-
51
-
-
21244495516
-
Indirect comparisons of competing interventions
-
iii-iv
-
Indirect comparisons of competing interventions. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ, Health Technol Assess 2005 9 26 1 134 iii-iv
-
(2005)
Health Technol Assess
, vol.9
, Issue.26
, pp. 1-134
-
-
Glenny, A.M.1
Altman, D.G.2
Song, F.3
Sakarovitch, C.4
Deeks, J.J.5
D'Amico, R.6
Bradburn, M.7
Eastwood, A.J.8
-
53
-
-
84872821987
-
-
London, UK: CRC Press/Chapman and Hall
-
Lunn D, Jackson C, Best N, Thoams A, D S: 8.6.4: DIC for model comparison. The BUGS Book-A Practical Introduction to Bayesian Analysis London, UK: CRC Press/Chapman and Hall 2013
-
(2013)
D S: 8.6.4: DIC for Model Comparison. The BUGS Book - A Practical Introduction to Bayesian Analysis
-
-
Lunn, D.1
Jackson, C.2
Best, N.3
Thoams, A.4
-
54
-
-
84904264995
-
-
The BUGS project Cambridge: MRC Biostatistics Unit
-
The BUGS project, DIC: Deviance Information Criterion Cambridge: MRC Biostatistics Unit 1996-2012
-
(1996)
DIC: Deviance Information Criterion
-
-
-
55
-
-
0031961926
-
Meta-analysis of multitreatment studies
-
DOI 10.1177/0272989X9801800110
-
Meta-analysis of multitreatment studies. Hasselblad V, Med Decis Making 1998 18 1 37 43 (Pubitemid 28041639)
-
(1998)
Medical Decision Making
, vol.18
, Issue.1
, pp. 37-43
-
-
Hasselblad, V.1
-
56
-
-
84867086419
-
Prior distributions for variance parameters in heirarchical models
-
Prior distributions for variance parameters in heirarchical models. Gelman A, Bayesian Anal 2006 1 3 515 533
-
(2006)
Bayesian Anal
, vol.1
, Issue.3
, pp. 515-533
-
-
Gelman, A.1
-
58
-
-
77949416255
-
Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: A meta-analysis of randomized clinical trials
-
Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. DeFronzo RA, Stonehouse AH, Han J, Wintle ME, Diabet Med 2010 27 3 309 317
-
(2010)
Diabet Med
, vol.27
, Issue.3
, pp. 309-317
-
-
Defronzo, R.A.1
Stonehouse, A.H.2
Han, J.3
Wintle, M.E.4
-
59
-
-
77953101143
-
Managing type 2 diabetes: Balancing HbA1c and body weight
-
Managing type 2 diabetes: balancing HbA1c and body weight. Mavian AA, Miller S, Henry RR, Postgrad Med 2010 122 3 106 117
-
(2010)
Postgrad Med
, vol.122
, Issue.3
, pp. 106-117
-
-
Mavian, A.A.1
Miller, S.2
Henry, R.R.3
-
60
-
-
84866424768
-
-
Dias S, Sutton AJ, Welton NJ, Ades AE, NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment 2011 http://www.nicedsu.org.uk
-
(2011)
NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-regression, Bias and Bias-adjustment
-
-
Dias, S.1
Sutton, A.J.2
Welton, N.J.3
Ades, A.E.4
-
61
-
-
7444228521
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
-
DOI 10.2337/diacare.27.11.2628
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group, Diabetes Care 2004 27 11 2628 2635 (Pubitemid 39441462)
-
(2004)
Diabetes Care
, vol.27
, Issue.11
, pp. 2628-2635
-
-
Buse, J.B.1
Henry, R.R.2
Han, J.3
Kim, D.D.4
Fineman, M.S.5
Baron, A.D.6
-
62
-
-
54249106294
-
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
-
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjornsdottir S, Camisasca RP, Couturier A, Baron MA, Diabetes Obes Metab 2008 10 11 1047 1056
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.11
, pp. 1047-1056
-
-
Garber, A.J.1
Foley, J.E.2
Banerji, M.A.3
Ebeling, P.4
Gudbjornsdottir, S.5
Camisasca, R.P.6
Couturier, A.7
Baron, M.A.8
-
63
-
-
34547863123
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
-
DOI 10.1111/j.1463-1326.2007.00744.x
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study G, Diabetes Obes Metab 2007 9 5 733 745 (Pubitemid 47261855)
-
(2007)
Diabetes, Obesity and Metabolism
, vol.9
, Issue.5
, pp. 733-745
-
-
Hermansen, K.1
Kipnes, M.2
Luo, E.3
Fanurik, D.4
Khatami, H.5
Stein, P.6
-
64
-
-
84866183265
-
Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: An 18-week, multicenter, randomized, double-blind, placebo-controlled trial
-
e1915
-
Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ, Clin Ther 2012 34 9 1909 1919 e1915
-
(2012)
Clin Ther
, vol.34
, Issue.9
, pp. 1909-1919
-
-
Lewin, A.J.1
Arvay, L.2
Liu, D.3
Patel, S.4
Von Eynatten, M.5
Woerle, H.J.6
-
65
-
-
84869745717
-
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
-
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. Clar C, Gill JA, Court R, Waugh N, BMJ open 2012 2 5 001007
-
(2012)
BMJ Open
, vol.2
, Issue.5
, pp. 5001007
-
-
Clar, C.1
Gill, J.A.2
Court, R.3
Waugh, N.4
-
66
-
-
84860183617
-
A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors: Systematic review and meta-analysis of randomized trials
-
A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Musso G, Gambino R, Cassader M, Pagano G, Ann Med 2012 44 4 375 393
-
(2012)
Ann Med
, vol.44
, Issue.4
, pp. 375-393
-
-
Musso, G.1
Gambino, R.2
Cassader, M.3
Pagano, G.4
-
67
-
-
84870508803
-
A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer
-
A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Alves C, Batel-Marques F, Macedo AF, Diabetes Res Clin Pract 2012 98 2 271 284
-
(2012)
Diabetes Res Clin Pract
, vol.98
, Issue.2
, pp. 271-284
-
-
Alves, C.1
Batel-Marques, F.2
Macedo, A.F.3
-
68
-
-
34447267513
-
Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
-
DOI 10.1001/jama.298.2.194
-
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori RE, Lau J, Pittas AG, JAMA 2007 298 2 194 206 (Pubitemid 47057766)
-
(2007)
Journal of the American Medical Association
, vol.298
, Issue.2
, pp. 194-206
-
-
Amori, R.E.1
Lau, J.2
Pittas, A.G.3
-
69
-
-
84873852937
-
Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: A pharmacological perspective
-
Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: a pharmacological perspective. Brown DX, Evans M, J Nutr Metab 2012 2012 381713
-
(2012)
J Nutr Metab
, vol.2012
, pp. 381713
-
-
Brown, D.X.1
Evans, M.2
-
70
-
-
79959773411
-
DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors
-
DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Dicker D, Diabetes Care 2011 34 Suppl 2 276 278
-
(2011)
Diabetes Care
, vol.34
, Issue.SUPPL. 2
, pp. 19276-19278
-
-
Dicker, D.1
-
71
-
-
84871158996
-
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: Systematic review and meta-analysis
-
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Gooßen K, Gräber S, Diabet Obes Metab 2012 14 1061 1072
-
(2012)
Diabet Obes Metab
, vol.14
, pp. 1061-1072
-
-
Gooßen, K.1
Gräber, S.2
-
72
-
-
0031927337
-
A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful
-
A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. Schade DS, Jovanovic L, Schneider J, J Clin Pharmacol 1998 38 7 636 641 (Pubitemid 28354902)
-
(1998)
Journal of Clinical Pharmacology
, vol.38
, Issue.7
, pp. 636-641
-
-
Schade, D.S.1
Jovanovic, L.2
Schneider, J.3
|